Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Development of leading first-generation vaccines against SARS-CoV-2

Microbes and Infection(2021)10.1016/j.micinf.2021.104841Source: DataRank Database

Development of leading first-generation vaccines against SARS-CoV-2 is a research paper published in Microbes and Infection (2021). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

refseq nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 0.00)OA: hybridTopics (39)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Liyanage P. Perera,Pin‐Yu Perera ORCID

Live enrichment

PubMed:34022375 PMC:PMC8133830 OpenAlex:https://openalex.org/W3165796223

National Institutes of Health

Grant: UL1TR001409-01

National Institutes of Health

Grant: UL1TR000101

NCATS NIH HHS

Grant: UL1 TR001409

National Institutes of Health

Grant: 3UL1TR001409-02S1

Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS)

National Institutes of Health

Grant: 3UL1TR000101-05S2

Georgetown-Howard Universities Center for Clinical and Translational Science (GHU

National Center for Advancing Translational Sciences

National Cancer Institute

U.S. Department of Veterans Affairs

FWCI

0.00

Citation Percentile

0.1%

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.micinf.2021.104841

publisherhttps://doi.org/10.1016/j.micinf.2021.104841

publisherhttps://api.elsevier.com/content/article/PII:S1286457921000630?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1286457921000630?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34022375

Fields of Study

SARS-CoV-2 and COVID-19 ResearchViral gastroenteritis research and epidemiologyAnimal Virus Infections Studies03 medical and health sciences0302 clinical medicineCOVID-19COVID-19 VaccinesHumansSARS-CoV-2

MeSH Terms

COVID-19SARS-CoV-2COVID-19 VaccinesHumans

Keywords

PandemicHerd immunitySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakBiologyVirologyImmunityClinical trialImmunologyIntensive care medicineMedicineVaccinationBioinformaticsImmune systemInfectious disease (medical specialty)DiseaseOutbreakVaccinesAnimal ModelsClinical TrialsCovid-19Sars-cov-2COVID-19 VaccinesHumansArticle

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being